nach oben

Diabetologia

Erschienen in:

01.03.2008 | Commentary

Aspirin resistance and diabetes mellitus

verfasst von: R. Ajjan, R. F. Storey, P. J. Grant

Erschienen in: Diabetologia | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Excerpt

Despite multiple interventions to reduce the risk of cardiovascular disease, the majority of people with diabetes develop macrovascular complications, and mortality following myocardial infarction remains unacceptably high [1]. Antiplatelet agents are used for both the primary and secondary prevention of cardiovascular disease, although current guidelines are not consistent in their recommendation for the use of aspirin in diabetes [2]. In fact, there is little direct evidence supporting its efficacy in this group of patients. Instead, there is convincing data in the literature to suggest inadequate cardiovascular protection by aspirin in diabetes. In a meta-analysis of 287 randomised trials, antiplatelet treatment (aspirin in most studies) reduced the risk of ischaemic events by 22%, but the risk reduction in the subgroup with diabetes was only 7%, which was not statistically significant [3]. This outcome was mirrored in the Primary Prevention Project trial, which reported that cardiovascular risk reduction with aspirin was marginal and non-significant in the presence of diabetes [4]. Despite this, there are no published studies specifically designed to evaluate the clinical efficacy of aspirin in individuals with diabetes, a surprising omission in the era of ‘evidence-based’ medicine. …

Cubbon RM, Wheatcroft SB, Grant PJ et al (2007) Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003. Eur Heart J 28:540–545PubMedCrossRef

Nicolucci A, De Berardis G, Sacco M, Tognoni G (2007) AHA/ADA vs ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. Eur Heart J 28:1925–1927PubMedCrossRef

Antithrombotic Trialists’ Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71–86CrossRef

Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A (2003) Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 26:3264–3272PubMedCrossRef

Mason PJ, Jacobs AK, Freedman JE (2005) Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 46:986–993PubMedCrossRef

Sanderson S, Emery J, Baglin T, Kinmonth AL (2005) Narrative review: aspirin resistance and its clinical implications. Ann Intern Med 142:370–380PubMed

Roth GJ, Siok CJ (1978) Acetylation of the NH₂-terminal serine of prostaglandin synthetase by aspirin. J Biol Chem 253:3782–3784PubMed

Patrono C, Ciabattoni G, Patrignani P et al (1985) Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 72:1177–1184PubMed

Kuster LJ, Frölich JC (1986) Platelet aggregation and thromboxane release induced by arachidonic acid, collagen, ADP and platelet-activating factor following low dose acetylsalicylic acid in man. Prostaglandins 32:415–423PubMedCrossRef

10.

Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM (1989) Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. Circulation 80:198–205PubMed

11.

Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT (1981) Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 304:685–691PubMed

12.

Chang J, Musser JH, McGregor H (1987) Phospholipase A₂: function and pharmacological regulation. Biochem Pharmacol 36:2429–2436PubMedCrossRef

13.

Barnes MJ, Knight CG, Farndale RW (1998) The collagen–platelet interaction. Curr Opin Hematol 5:314–320PubMedCrossRef

14.

Lages B, Weiss HJ (1981) Dependence of human platelet functional responses on divalent cations: aggregation and secretion in heparin- and hirudin-anticoagulated platelet-rich plasma and the effects of chelating agents. Thromb Haemost 45:173–179PubMed

15.

Storey RF (2006) Biology and pharmacology of the platelet P2Y₁₂ receptor. Curr Pharm Des 12:1255–1259PubMedCrossRef

16.

Fatah K, Silveira A, Tornvall P, Karpe F, Blomback M, Hamsten A (1996) Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 76:535–540PubMed

17.

Collet JP, Park D, Lesty C et al (2000) Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 20:1354–1361PubMed

18.

He S, Blomback M, Yoo G, Sinha R, Henschen-Edman AH (2001) Modified clotting properties of fibrinogen in the presence of acetylsalicylic acid in a purified system. Ann N Y Acad Sci 936:531–535PubMedCrossRef

19.

Antovic A, Perneby C, Ekman GJ et al (2005) Marked increase of fibrin gel permeability with very low dose ASA treatment. Thromb Res 116:509–517PubMedCrossRef

20.

Williams S, Fatah K, Hjemdahl P, Blomback M (1998) Better increase in fibrin gel porosity by low dose than intermediate dose acetylsalicylic acid. Eur Heart J 19:1666–1672PubMedCrossRef

21.

Pinckard RN, Hawkins D, Farr RS (1968) In vitro acetylation of plasma proteins, enzymes and DNA by aspirin. Nature 219:68–69PubMedCrossRef

22.

Kessels H, Beguin S, Andree H, Hemker HC (1994) Measurement of thrombin generation in whole blood—the effect of heparin and aspirin. Thromb Haemost 72:78–83PubMed

23.

Undas A, Sydor WJ, Brummel K, Musial J, Mann KG, Szczeklik A (2003) Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism. Circulation 107:17–20PubMedCrossRef

24.

Fateh-Moghadam S, Plockinger U, Cabeza N et al (2005) Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 42:99–103PubMedCrossRef

25.

Mehta SS, Silver RJ, Aaronson A, Abrahamson M, Goldfine AB (2006) Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol 97:567–570PubMedCrossRef

26.

Fontana P, Nolli S, Reber G, de Moerloose P (2006) Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Thromb Haemost 4:813–819PubMedCrossRef

27.

Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A (2005) Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 95:973–975PubMedCrossRef

28.

Ohmori T, Yatomi Y, Nonaka T et al (2006) Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 4:1271–1278PubMedCrossRef

29.

DiMinno G, Silver MJ, Cerbone AM, Murphy S (1986) Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 68:886–891PubMed

30.

Ajjan R, Grant PJ (2006) Coagulation and atherothrombotic disease. Atherosclerosis 186:240–259PubMedCrossRef

31.

Dunn EJ, Philippou H, Ariens R, Grant PJ (2006) Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 49:1071–1080PubMedCrossRef

32.

Rendell M, Nierenberg J, Brannan C et al (1986) Inhibition of glycation of albumin and hemoglobin by acetylation in vitro and in vivo. J Lab Clin Med 108:286–293PubMed

33.

Swamy-Mruthinti S, Carter AL (1999) Acetyl-l-carnitine decreases glycation of lens proteins: in vitro studies. Exp Eye Res 69:109–115PubMedCrossRef

34.

Watala C, Boncler M, Gresner P (2005) Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacol Rep 57(Suppl):42–58PubMed

35.

Watala C, Pluta J, Golanski J et al (2005) Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med 83:148–158PubMedCrossRef

36.

Watala C, Ulicna O, Golanski J et al (2006) High glucose contributes to aspirin insensitivity in streptozotocin-diabetic rats: a multiparametric aggregation study. Blood Coagul Fibrinolysis 17:113–124PubMedCrossRef

37.

Watala C, Golanski J, Pluta J et al (2004) Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)—its relation to metabolic control. Thromb Res 113:101–113PubMedCrossRef

38.

Takahashi S, Ushida M, Komine R et al (2007) Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. Thromb Res 119:517–524PubMedCrossRef

39.

Gum PA, Kottke-Marchant K, Poggio ED et al (2001) Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88:230–235PubMedCrossRef

40.

Early Treatment Diabetic Retinopathy Study Investigators (1992) Aspirin effects on mortality and morbidity in patients with diabetes mellitus. ETDRS report 14. JAMA 268:1292–1300CrossRef

41.

Evangelista V, Totani L, Rotondo S et al (2005) Prevention of cardiovascular disease in type 2 diabetes: how to improve the clinical efficacy of aspirin. Thromb Haemost 93:8–16PubMed

42.

Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ (2002) Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 90:625–628PubMedCrossRef

43.

Laine L (2006) Gastrointestinal bleeding with low dose aspirin—what’s the risk? Aliment Pharmacol Ther 24:897–908PubMedCrossRef

Titel: Aspirin resistance and diabetes mellitus
verfasst von: R. Ajjan
R. F. Storey
P. J. Grant
Publikationsdatum: 01.03.2008
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 3/2008
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-007-0898-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2008

Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy

Candidate gene studies reveal that the WFS1 gene joins the expanding list of novel type 2 diabetes genes

Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients

Can persistent organic pollutants explain the association between serum γ-glutamyltransferase and type 2 diabetes?

USF1 gene variants contribute to metabolic traits in men in a longitudinal 32-year follow-up study